CWA Asset Management Group LLC Takes $1.67 Million Position in Lantheus Holdings, Inc. $LNTH

CWA Asset Management Group LLC bought a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) during the 4th quarter, HoldingsChannel reports. The institutional investor bought 25,096 shares of the medical equipment provider’s stock, valued at approximately $1,670,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Hantz Financial Services Inc. lifted its position in Lantheus by 412.5% in the third quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 396 shares during the last quarter. Elevation Point Wealth Partners LLC purchased a new position in Lantheus during the second quarter worth $26,000. First Horizon Corp bought a new position in Lantheus during the third quarter valued at $26,000. Osterweis Capital Management Inc. bought a new position in Lantheus during the second quarter valued at $36,000. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in shares of Lantheus in the third quarter valued at $55,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Stock Down 2.0%

Shares of LNTH opened at $76.43 on Monday. The firm has a fifty day moving average price of $71.53 and a 200-day moving average price of $62.65. The company has a current ratio of 2.70, a quick ratio of 2.51 and a debt-to-equity ratio of 0.52. The firm has a market capitalization of $4.98 billion, a P/E ratio of 22.68 and a beta of -0.11. Lantheus Holdings, Inc. has a 12-month low of $47.25 and a 12-month high of $108.91.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Thursday, February 26th. The medical equipment provider reported $1.67 EPS for the quarter, topping the consensus estimate of $1.17 by $0.50. Lantheus had a net margin of 15.15% and a return on equity of 30.77%. The company had revenue of $406.79 million for the quarter, compared to the consensus estimate of $367.03 million. During the same quarter last year, the firm posted $1.59 EPS. The firm’s revenue was up 4.0% compared to the same quarter last year. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Equities research analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Wall Street Analyst Weigh In

LNTH has been the subject of several analyst reports. William Blair restated an “outperform” rating on shares of Lantheus in a report on Tuesday, March 17th. Wall Street Zen lowered shares of Lantheus from a “strong-buy” rating to a “buy” rating in a research report on Sunday, March 15th. Mizuho raised their price objective on shares of Lantheus from $72.00 to $85.00 and gave the stock an “outperform” rating in a research note on Friday, February 27th. Weiss Ratings upgraded Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, January 6th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $110.00 target price on shares of Lantheus in a research note on Tuesday, March 17th. Eight investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $86.14.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.